Home › Compare › NICLF vs ABBV
NICLF yields 1694.92% · ABBV yields 3.06%● Live data
📍 NICLF pulled ahead of the other in Year 1
Combined, NICLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NICLF + ABBV for your $10,000?
Class 1 Nickel and Technologies Limited engages in the exploration and development of minerals and base metals in Canada. The company explores for nickel, copper, and cobalt sulphide deposits. It primarily holds a 100% interest in the Alexo-Dundonald project, comprising 95 Boundary Cell Mining Claims, Single Cell Mining Claims, Leased Claims, and Patented Claims, which covers an approximately 1,895 hectares located to the northeast of Timmins, Ontario. It also holds option to acquire 100% interest in the Somanike Project located in the Abitibi Region of Quebec, and 100% interest in the River Valley PGE Project located to northeastern Ontario, Canada. The company was formerly known as Legendary Ore Mining Corporation and changed its name to Class 1 Nickel and Technologies Limited in September 2019. Class 1 Nickel and Technologies Limited was incorporated in 1989 and is headquartered in Toronto, Canada.
Full NICLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.